 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || TMP-301 / Tempero Bio
Enrollment closed: Multiple Ascending Dose Study of TMP-301 in Healthy Subjects (clinicaltrials.gov) - Dec 11, 2023
P1, N=32, Active, not recruiting, Sponsor: Tempero Bio, Inc.
Recruiting --> Active, not recruiting
- || TMP-301 / Tempero Bio
Enrollment open: Multiple Ascending Dose Study of TMP-301 in Healthy Subjects (clinicaltrials.gov) - Sep 14, 2023
P1, N=32, Recruiting, Sponsor: Tempero Bio, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- | TMP-301 / Tempero Bio
New P1 trial: Multiple Ascending Dose Study of TMP-301 in Healthy Subjects (clinicaltrials.gov) - Sep 6, 2023
P1, N=32, Active, not recruiting, Sponsor: Tempero Bio, Inc.
- || TMP-301 / Tempero Bio
Trial completion: Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects (clinicaltrials.gov) - Jul 7, 2021
P1, N=8, Completed, Sponsor: Heptares Therapeutics Limited
Active, not recruiting --> Recruiting Recruiting --> Completed
- | Preclinical, Journal: Understanding exposure-receptor occupancy relationships for metabotropic glutamate receptor 5 (mGlu) negative allosteric modulators across a range of pre-clinical and clinical studies. (Pubmed Central) - May 15, 2021
Significance Statement Despite the long history of mGlu as a therapeutic target and progression of multiple compounds to the clinic, no formal comparison of exposure-receptor occupancy relationships has been conducted. Our data indicate for the first time that a consistent, unified relationship can be observed between exposure and mGlu receptor occupancy when unbound brain concentration and receptor affinity are taken into account across a range of species for a diverse set of mGlu NAMs, including a new drug candidate, HTL0014242.
- ||| TMP-301 / Tempero Bio
Trial completion: Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242 (clinicaltrials.gov) - Apr 29, 2021
P1, N=71, Completed, Sponsor: Heptares Therapeutics Limited
Our data indicate for the first time that a consistent, unified relationship can be observed between exposure and mGlu receptor occupancy when unbound brain concentration and receptor affinity are taken into account across a range of species for a diverse set of mGlu NAMs, including a new drug candidate, HTL0014242. Recruiting --> Completed
- | TMP-301 / Tempero Bio
Trial completion date, Trial primary completion date: Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects (clinicaltrials.gov) - Apr 22, 2021
P1, N=10, Recruiting, Sponsor: Heptares Therapeutics Limited
Recruiting --> Completed Trial completion date: Mar 2021 --> Aug 2021 | Trial primary completion date: Mar 2021 --> Aug 2021
- || TMP-301 / Tempero Bio
Trial completion date, Trial primary completion date: Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242 (clinicaltrials.gov) - Oct 26, 2020
P1, N=78, Recruiting, Sponsor: Heptares Therapeutics Limited
Trial completion date: Mar 2021 --> Aug 2021 | Trial primary completion date: Mar 2021 --> Aug 2021 Trial completion date: May 2020 --> May 2021 | Trial primary completion date: Apr 2020 --> Jan 2021
- | TMP-301 / Tempero Bio
Trial completion date, Trial primary completion date: Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects (clinicaltrials.gov) - Oct 26, 2020
P1, N=10, Recruiting, Sponsor: Heptares Therapeutics Limited
Trial completion date: May 2020 --> May 2021 | Trial primary completion date: Apr 2020 --> Jan 2021 Trial completion date: Nov 2020 --> Mar 2021 | Trial primary completion date: Nov 2020 --> Mar 2021
- | HTL0014242 / Sosei
Journal: Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulators. (Pubmed Central) - Oct 1, 2020
An alternative approach to drug discovery is to use structural knowledge to enable structure-based drug design (SBDD), which allows the design of molecules in a more rational, rather than empirical, fashion. Here we will describe the process of SBDD in the discovery of the mGlu negative allosteric modulator HTL0014242 and describe how knowledge of receptor structure can also be used to gain insights into the receptor activation mechanisms.
- || TMP-301 / Tempero Bio
New P1 trial: Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects (clinicaltrials.gov) - Jul 7, 2020
P1, N=10, Recruiting, Sponsor: Heptares Therapeutics Limited
- || TMP-301 / Tempero Bio
Enrollment change, Trial completion date, Trial primary completion date: Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242 (clinicaltrials.gov) - Nov 9, 2019
P1, N=78, Recruiting, Sponsor: Heptares Therapeutics Limited
Here we will describe the process of SBDD in the discovery of the mGlu negative allosteric modulator HTL0014242 and describe how knowledge of receptor structure can also be used to gain insights into the receptor activation mechanisms. N=48 --> 78 | Trial completion date: Aug 2019 --> May 2020 | Trial primary completion date: Jul 2019 --> Apr 2020
- || TMP-301 / Tempero Bio
New P1 trial: Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242 (clinicaltrials.gov) - Dec 24, 2018
P1, N=48, Recruiting, Sponsor: Heptares Therapeutics Limited